Management of type 2 diabetes patients: current perspective and futuristic promise of combination therapies with DPP-IV inhibitors.
Keywords:
Vildagliptin, secretagogues, insulin, diabetes mellitus, DPP-IV inhibitorsAbstract
Mechanism of action of the currently available therapeutic drugs for treatment of T2DM varies from being insulin secretogogues to insulin sensitization or reduction in insulin requirement. Often the diabetes treatment goals are not met due to adverse effects of current therapies like hypoglycemia, cardiovascular risks, weight gain etc. Metformin-based combination therapy with DPP-IV inhibitors vildagliptin has shown more efficacy than monotherapy for effective T2DM treatment as the two acts synergistically and using altogether different mechanisms of actions leading to augmentation of incretin effect and increased β- cell mass as well as increased sensitivity to insulin leading to improved hyperglycaemic control, has no adverse effects and is relatively safe.
Downloads
References
Abbasi F, Carantoni M, Chen YD, Reaven GM. Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin. Diabetes Care 1998; 21: 1301-1305.
Ahrén B, Pacini G, Tura A, et al. Improved meal-related insulin processing contrib utes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in pa tients with type 2 diabetes. Horm Metab Res 2007; 39: 826–829.
Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004; 36: 867–76.
Ahrén B.Dipeptidyl peptidase-4 inhibitors – clinical data and clinical implications. Diabetes Care 2007a; 30:1344–1350.
American Diabetes Association. Facts and Figures. .
American Diabetes Association. Clinical Practice Recommendations 2000. Diabetes Care 2000; 23 (Suppl 1): S1–S116.
Asian-Pacific Type 2 Diabetes Policy Group. Type 2 diabetes. Practical targets and Treatments, edn 3. Sydney: Health Communications Australia Pty Ltd and In vivo, 2002.
Bosi E, Camisasca RP, Collober C, et al. Effects of vlidagliptin on glucose control over 24 weeks in patients with type 2 diabetes in adequatelycontrolled with met formin. Diabetes Care 2007; 30: 890–895.
Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, Martin J. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002; 24: 378-396
Brazg R, Xu L, Dalla Man C, et al. Effect of add ingsitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and β-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 186–193.
Butler PC, Rizza RA. Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 1991; 40: 73-81.
Center for Disease Control and Prevention. National Center for Chronic Disease Prevention and Health Promotion. Frequently Asked Questions. .
Chantal Mathieu Evy Degrande, Vildagliptin: a new oral treatment for type 2 diabetes mellitus. Vascular Health and Risk Management 2008:4(6) 1349–1360.
Charbonnel B, Wu M, Karasik A, et al. Efficacy and safety of the dipeptidyl pepti dase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638–43.
Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997; 102: 99-110.
DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-549.
DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28:1092–100.
Del Prato S, Marchetto S, Pipitone A, Zanon M, Vigili de Kreutzenberg S, Tiengo A. Metformin and free fatty acid metabolism. Diabetes Metab Rev 1995; 11: S33-S41.
Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006; 55: S20–S27.
Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in non-insulin dependent diabetes mellitus. N Engl J Med 1992; 327: 707-713.
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696–1705.
Dunning BE, Foley J, Ahrén B. Alpha-cell function in health and disease: influence of GLP-1. Diabetologia 2005; 48:1700–1713.
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
European Diabetes Policy Group. A desktop guide to Type 1 (insulin-dependent) diabetes mellitus. Diabetic Medicine 1999; 16: 253–266.
Fenglos MM, Saad MF, Pi-Sinyer FX, et al. Effects of liragflutide (NN2211) , a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes. Diabet Med 2005; 22: 1016–1023.
Firth RG, Bell PM, Marsh HM, Hansen I, Rizza RA. Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus: role of hepatic and extrahepatic tissues. J Clin Invest 1986; 77: 1525-1532.
Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283: 1695-1702.
Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose response trial. Am J Med 1997; 103: 491-497.
Green Brian, Flatt Peter, Bailey Clifford. Gliptins: DPP-4 inhibitors to treat type 2 diabetes. Future prescriber, 2008; 8: 6-12.
Green JB, Feinglos MN. Are sulphonylureas passé? Curr Diabet Rep 2007; 6: 373–377.
Herman GA, Bergman A, Yi B, et al. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase 4 inhibitor sitagliptin when co-adminis tered in patients with type 2 diabetes. Curr Med Res Opin 2006; 22: 1939–1947.
Hermann LS, Scherste ´n B, Bitze ´n PO, Kjellstro ¨m T, Lindga ¨rde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994; 17: 1100-1109.
Hinke SA, Kuhn-Wache K, Hoffman T, et al. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002; 291: 1302–1308.
Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase- IV as a treatment for type 2 diabetes. Diabetes 1998; 47: 1663-1170.
Hundal RS, Inzucchi SE. 2003. Metformin: new understandings, new uses Drugs 63:1879–94.
Johansen K. Efficacy of metformin in the treatment of NIDDM. Meta analysis. Diabetes Care 1999; 22: 33-37.
Kahn SE, Haffner, SM, Helse MA, et al. Glycemic durabil ity of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427–2443.
Kahn SE. The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001; 86:4047–58.
Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25: 708- 711.
Kothny W, Gimpelewicz CR, Byiers S, Mills D, Fitchet M. Cardiovascular safety profile of vildagliptin, a new DPP-4 inhibitor for the treatment of type 2 diabetes. Poster presented at: European Association for the study Diabetes–44th Annual Scientific Sessions; September 7–11, 2008; Rome, Italy. Poster P-915.
Krentz AJ, Bailey CJ, Oral antidiabetic agents. Current role in type 2 diabetes mellitus, Drugs 2005; 65: 385–411.
LaCivita KA, Villarreal G. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Curr Med Res Opin 2002; 18: 363-370.
Leverve KM, Guigas B, Detaille D, et al. Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 2003; 29: 6S88–94.
Levetran C. Oral antidiabeti agents in type 2 diabetes. Curr Med Res Opin 2007; 23:945–952.
Lindsay JR, Duffy NA, McKillop AM, et al. Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes. Diabet Med 2005; 22: 654–657.
Mannucci E, Pierazzuoli E, Ognibene A, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24:489–494.
Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888–94.
Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
McIntosh A, Hutchinson A, Home PD, Brown F, Bruce A, Damerell A, Davis R, Field R, Frost G, Marshall S, Roddick J, Tesfaye S, Withers H, Suckling R, Smith S, Griffin S, Kaltenthaler E, Peters J & Feder G. Clinical guidelines and evidence review for Type 2 diabetes: management of blood glucose. Sheffield: ScHARR, University of Sheffield, 2001.
Migoya EM, Miller J, Larson P, et alSitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations. Diabetes 2007; 56(Suppl 1): A74.
Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima , Furuyoshi N & Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Research and Clinical Practice 1995; 28; 103–117.
Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85: 2767-2774.
Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 2004; 36: 804–810.
Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all cause mortality? A meta-analysis of observational studies. Diabetes Care 2008; 31: 1672–1678.
Selby JV, Ettinger B, Swain BE, Brown JB. First 20 months’ experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care 1999; 22: 38-44.
Setter SM, Iltz JL, Thams J, et al. 2003. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dualtherapy. Clin Ther 25:2991–3026.
Stratton IM, Adler AI, Neil HA, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321: 405–12.
UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 837–853.
United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310: 83-88.
US) FDA News. FDA issues safety alert on Avandia, May 21, 2007. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01636.html.Last accessed on 01 December 2008.
WHO, http://www.who.int/diabetes/facts/world_figures/en/index.html
Yamasaki Y, Kawamori R, Wasada T, Sato A, Omori Y, Eguchi H, Tominaga M, Sasaki H, Ikeda M, Kubota M, Ishida Y, Hozumi T, Baba S, Uehara M, Shichiri M, Kaneko T; Glucose Clamp Study Group, Japan. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Tohoku J Exp Med 1997; 183: 173-183.
Yki-Ja ¨rvinen H, Nikkila ¨K,Ma ¨kimattila S. Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus. Drugs 1999; 58 Suppl 1: 53-54; discussion 75-82.
Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997; 26: 511-522.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Rigzin Kang, Gaganjot Singh Kalsey
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license unless indicated otherwise in a credit line to the material. If the material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/ licenses/by/4.0/
